Paula Dowdy Acquires 109,890 Shares of Quantum-Si (NASDAQ:QSI) Stock

Quantum-Si Incorporated (NASDAQ:QSI) Director Paula Dowdy bought 109,890 shares of Quantum-Si stock in a transaction that occurred on Thursday, March 5th. The shares were acquired at an average cost of $0.95 per share, for a total transaction of $104,395.50. Following the completion of the transaction, the director directly owned 269,107 shares in the company, valued at $255,651.65. This represents a 69.02% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Quantum-Si Stock Performance

Shares of NASDAQ QSI opened at $0.87 on Monday. The company has a market cap of $188.36 million, a PE ratio of -1.68 and a beta of 3.00. The business has a 50-day simple moving average of $1.10 and a two-hundred day simple moving average of $1.37. Quantum-Si Incorporated has a fifty-two week low of $0.84 and a fifty-two week high of $3.10.

Quantum-Si (NASDAQ:QSI) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Quantum-Si had a negative return on equity of 43.90% and a negative net margin of 4,160.06%.The business had revenue of $0.45 million for the quarter, compared to analyst estimates of $0.76 million. On average, sell-side analysts predict that Quantum-Si Incorporated will post -0.65 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on QSI shares. Weiss Ratings restated a “sell (d-)” rating on shares of Quantum-Si in a research note on Monday, December 29th. Canaccord Genuity Group lowered their price objective on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a research note on Wednesday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Quantum-Si presently has an average rating of “Hold” and a consensus price target of $3.25.

Institutional Investors Weigh In On Quantum-Si

Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC purchased a new stake in Quantum-Si in the first quarter valued at approximately $4,721,000. State Street Corp raised its position in Quantum-Si by 26.5% during the 4th quarter. State Street Corp now owns 3,562,721 shares of the company’s stock worth $3,919,000 after buying an additional 745,231 shares during the last quarter. Squarepoint Ops LLC purchased a new position in Quantum-Si during the 3rd quarter worth approximately $865,000. Geode Capital Management LLC lifted its stake in Quantum-Si by 15.1% during the 2nd quarter. Geode Capital Management LLC now owns 3,447,738 shares of the company’s stock valued at $6,759,000 after acquiring an additional 452,850 shares during the period. Finally, Bank of America Corp DE lifted its stake in Quantum-Si by 426.6% during the 2nd quarter. Bank of America Corp DE now owns 465,999 shares of the company’s stock valued at $913,000 after acquiring an additional 377,504 shares during the period. Institutional investors and hedge funds own 39.90% of the company’s stock.

About Quantum-Si

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.